Stressful events experienced early in life can dramatically alter the functioning of the HPA axis, which regulates the stress response and influences the perception of pain (Heim et al., 1998, 2001; Rao et al., 2008; Tyrka et al., 2008; Mayson and Teichman, 2009; Videlock et al., 2009; schematically shown in Figure 1). Corticotropin-releasing factor (CRF) is the primary initiator of the stress response and, in the brain, is primarily expressed in the paraventricular nucleus (PVN) of the hypothalamus, central nucleus of the amygdala (Bale and Vale, 2004), and Barrington’s nucleus (BN), the pontine micturition center (Imaki et al., 1991; Pavcovich and Valentino, 1995). Under stressful conditions, CRF and arginine vasopressin are secreted from the PVN of the hypothalamus and travel through the hypophysical portal veins to reach the anterior pituitary corticotrophs and induce the release of adrenocorticotropic hormone (ACTH). Systemic circulation of ACTH stimulates the production and release of glucocorticoids (GC, cortisol in humans and corticosterone in rodents) from the adrenal cortex (Herman et al., 2005; Ulrich-Lai and Herman, 2009), which, under normal conditions, initiate an overall immune suppression and decrease CRF and ACTH production through a negative feedback loop (Kageyama and Suda, 2009; Tasker and Herman, 2011).

In addition to CRF, its family members, the urocortins (Ucn1–3), are also produced in stress-related brain regions. Ucn2 and Ucn3 are found in the PVN (Reyes et al., 2001; Venihaki et al., 2004) and Ucn1 is largely expressed in Edinger-Westphal, superior lateral olive, and supraoptic nuclei (Vaughan et al., 1995; Bittencourt et al., 1999). It has been hypothesized that CRF and Ucn1 comprise two separate and functionally intertwined stress-responsive neuronal circuits, as Ucn1 mRNA levels are upregulated in the Edinger-Westphal nucleus following acute pain and/or restraint stress, but on a delayed and longer time scale than CRF is increased in the PVN (Kozicz, 2007). Two G-protein coupled receptors, CRF₁ and CRF₂, bind CRF and Ucn ligands with varying affinity. CRF binds CRF₁ with a 10-fold higher affinity than CRF₂, Ucn1 binds CRF₁ and CRF₂ with equal affinity, and Ucn2 and Ucn3 both preferentially bind CRF₂ (Bale and Vale, 2004). Opposing roles of CRF₁ and CRF₂ in stress-related behaviors have been defined through gene deletion and pharmacological studies. Disruption of CRF₁ signaling is largely anxiolytic and results in a significant decrease in anxiety-like behaviors (Smith et al., 1998). In contrast, CRF₂ deletion or blockade increases behavioral indicators of anxiety and prevents homeostatic resolution within HPA axis following a stressful event (Bale et al., 2000, 2002). Stress exposure also promotes CRF release in the central amygdala, a limbic structure involved in memory processing, decision-making, and emotional reactions (Cook, 2004). Chronic GC exposure increases expression of CRF mRNA in the amygdala (Makino et al., 1994, 1999), suggesting that sensitization may be involved in the development of stress-related pathologies (Herman et al., 2012). Studies have also described central activation of CRF receptors mediating stress-related changes in GI function (Van Pett et al., 2000; Reyes et al., 2008). Additionally, studies in children exposed to severe deprivation, neglect, or abuse report lower baseline levels of GCs (Gunnar and Quevedo, 2008; Lupien et al., 2009). It has been hypothesized that this may be due to a downregulation of the HPA axis at the level of the pituitary in response to chronic drive of CRF from the hypothalamus (Fries et al., 2005), or target tissue hypersensitivity to GCs (Yehuda et al., 2006).

Glucocorticoid receptors (GRs) are also abundantly expressed in the hypothalamus and limbic structures and respond to systemic and diurnal release of GCs from the adrenal cortex. The high-affinity mineralocorticoid receptor (MR) can be bound at low circulating levels of GCs, and is thus thought to be important in ambient GC signaling (Dallman et al., 1989) and maintaining the diurnal tone of the HPA axis (Reul and de Kloet, 1985). Tonic feedback within the HPA axis via hippocampal MR is thought to occur by dampening HPA activity during the diurnal trough (van Haarst et al., 1997). The lower-affinity GR is bound during diurnal peaks and spikes in GCs following an acute stressor (Reul and de Kloet, 1985; De Kloet et al., 1998). GR is richly expressed throughout the hippocampus and the prefrontal cortex, limbic structures that are implicated in negative feedback regulation of the HPA axis (Herman, 1993; Herman et al., 2012). Through electrical and chemical stimulation, genetic manipulation, and lesion studies, these brain regions have been shown to be responsible for negative feedback inhibition of the stress response through GR binding, likely in parallel due to innervation of common subcortical targets (Radley and Sawchenko, 2011; Herman et al., 2012). Both MR and GR are highly expressed in hippocampal neurons that, when activated, shut down the HPA axis following the resolution of stressful stimuli by glutamatergic input to GABAergic PVN relays within the hypothalamus (Cho and Little, 1999; Kohara et al., 2001; Numakawa et al., 2009). Negative feedback inhibition of the HPA axis from limbic circuitry is programmed during development and can permanently alter HPA axis function, making the limbic system particularly vulnerable to adversity early in life (Perry and Pollard, 1998; Vázquez, 1998; Bremne and Vermetten, 2001; Heim and Nemeroff, 2002; Teicher et al., 2002, 2003; Rao et al., 2008; Rincón-Cortés and Sullivan, 2014).

CRF₁ and CRF₂ are also widely distributed in the periphery, where ligand-binding activation influences evolutionarily conserved mammalian physiological mechanisms that mediate the return to homeostasis following a stressful event. In the rat colon, CRF₁ immunoreactivity was observed in the mucosal layer, primarily in cells of an inflammatory nature, and in the myenteric plexus and submucosal plexus; whereas, CRF₂ immunoreactivity was observed on the luminal surface of goblet cells and in blood vessels located in the submucosa, but not in the enteric innervation (Chatzaki et al., 2004). Expression of CRF₁ has been confirmed in submucosal and myenteric neurons of the human colon and by macrophages in the lamina propria (Yuan et al., 2012). Exogenous application of CRF or plasma from IBS patients stimulated contractility of explanted rat colon, the latter of which could be blocked by CRF₁, but not CRF₂, antagonist pretreatment (Buckley et al., 2014). In the same study, blocking interleukin (IL)-6 or CRF alleviated the increased gastrointestinal motility and improved visceral pain thresholds in a Wistar-Kyoto rat model of IBS. Increased transepithelial resistance and mucosal-to-serosal flux was observed in porcine ileus explants following exposure to increasing amounts of CRF, which was blocked by a non-selective CRF_1/2 antagonist or a mast cell stabilizer (Overman et al., 2012). Feline urothelial cells also express functionally-active CRF₁ and CRF₂, along with their intrinsic ligands CRF and Ucn1 (Hanna-Mitchell et al., 2014). Samples from cats with feline interstitial cystitis, widely accepted as the most relevant preclinical model of IC, demonstrated alterations in CRF receptor expression and functioning, suggesting an etiological role for CRF signaling in this disorder. In human peripheral tissues, CRF₂ is expressed in high levels in the skin and muscles (skeletal, smooth and cardiac), whereas CRF₁ is expressed in tissues such as adrenal, adipose tissue, the gonads, endometrium, myometrium, placenta, skin, spleen, and specific cells of the immune system (Hillhouse and Grammatopoulos, 2006).

One downstream target of the HPA axis that has been implicated in nearly all chronic pelvic pain syndromes is the mast cell. Mast cells are multifunctional immune cells that express high-affinity immunoglobulin E receptors and release potent inflammatory mediators including, but not limited to, leukotrienes, cytokines, serotonin, histamine, and proteases, such as tryptase (Ren et al., 1998). Involved in the innate immune response, hematopoietic progenitors of mast cells develop in the bone marrow and are recruited to the peripheral tissues, primarily those interfacing with the environment (e.g., the respiratory-, gastrointestinal-, and genitourinary tracts), where they take up residence and undergo maturation following a complex network of signaling and transcription factors (Tore et al., 2001; Beghdadi et al., 2011). Mast cells are highly responsive to activation of the HPA axis, as they express five isoforms of the CRF₁ receptor, a single isoform of the CRF₂ receptor, and contain one of the largest peripheral stores of CRF (Theoharides et al., 2004). The hallmark form of mast cell activation is through degranulation and release of their intracellular stores; however, stress can induce release of cytokines and growth factors in the absence of partial or complete degranulation (Theoharides et al., 2004; Anand et al., 2012). As mast cells are often found in close proximity to nerves and their contents are known to act on nociceptive fibers, it is strongly asserted that mast cells play a key role in peripheral sensitization in chronic pain. Biopsies of affected tissues from patients with IBS (Barbara et al., 2004), IC/PBS (Anand et al., 2012), vulvodynia (Goetsch et al., 2010), and CP/CPPS (Done et al., 2012) have all shown increased mast cell infiltration, degranulation, and/or exuded contents.

IBS is the most commonly diagnosed chronic pelvic pain disorder, as well as functional gastrointestinal disorder. IBS is characterized by chronic or recurrent abdominal pain or discomfort and altered bowel habits. Symptom onset or exacerbation is often triggered by stress in patients suffering from IBS (Mayer et al., 2001; Blanchard et al., 2008; Dufton et al., 2008; Stasi et al., 2012; Fond et al., 2014). A reported history of early life stress, such as premature birth, neglect, abuse, loss of a parent, or parental discord, is a significant risk factor for developing IBS in adulthood (Barreau et al., 2007; Chitkara et al., 2008; Videlock et al., 2009). Premature birth or low birth weight increases the risk of developing IBS, in part due to a developmentally immature gastrointestinal system at birth (Berseth, 1989; Bengtson et al., 2006). Gastric suctioning shortly after birth can also increase the risk of developing functional gastrointestinal disorders (Anand et al., 2004).

Improper functioning of the HPA axis, particularly over-activity, has been noted in sub-populations of IBS sufferers. In a study that investigated the impact of childhood trauma on HPA axis responsiveness in IBS patients, subjects that reported early adverse life events had significantly higher salivary cortisol levels following sigmoidoscopy than control patients (Videlock et al., 2009). In those patients with IBS, a faster resolution of stress-induced cortisol correlated with lower symptom severity and higher quality of life ratings. Furthermore, over-activation of the HPA axis was more related to a history of early life adverse events than to the presence of IBS, suggesting that exposure to early life stress alone may not be sufficient for the manifestation of IBS. In a separate study that did not interrogate the role of early life stress exposure, female IBS patients had significantly lower basal ACTH levels, but higher basal and stimulated plasma cortisol levels. They also displayed a positive correlation between plasma cortisol and reported anxiety levels prior to sigmoidoscopy (Chang et al., 2009). Based on preclinical rodent studies, increased CRF/CRF₁ signaling in both the brain and colon has been proposed to contribute towards comorbid anxiety/depression in female diarrhea-predominant IBS patients (Taché et al., 2005). Clinical studies looking at the effectiveness of CRF₁ antagonist treatment have had mixed success in patients. An initial study reported no effect of CRF₁ antagonist on influencing colonic transit time, stool frequency, or consistency in female diarrhea-predominant IBS patients (Sweetser et al., 2009). Reported anxiety and depression scores were not different between placebo and treatment groups; however, the authors state that 7/30 patients reported anxiety scores that indicate significant anxiety. Considering the role of comorbidity in HPA axis over-activity, it would have been informative to determine whether the CRF₁ antagonist was more or less effective in these highly anxious patients. A later study addressed this relationship by measuring the effectiveness of a CRF₁ antagonist on mediating the functional connectivity of the emotional-arousal circuit using fMRI prior to the expectation of abdominal pain (Hubbard et al., 2011). In this study, the CRF₁ antagonist, relative to placebo, significantly reduced the blood oxygen level-dependent signal in the hypothalamus in IBS patients with average or high levels of anxiety during expectation of abdominal pain. The authors suggested that their findings, when compared to previous, negative outcomes with CRF₁ antagonists, support the idea that targeting the CRF/CRF₁ signaling pathway may only be beneficial in a subset of patients who also display stress sensitivity, anxiety, and hyper-responsiveness of the HPA axis. These studies emphasize the etiologic heterogeneity underlying IBS, despite similar symptomology. Further understanding of IBS and comorbidities will be essential in designing appropriate, personalized treatment strategies.

Due to the significant impact of early life stress on IBS development, NMS is a frequently used preclinical model for understanding the mechanisms underlying early life stress-induced gastrointestinal hypersensitivity and dysfunction. Adult rodents that were exposed to NMS exhibit many of the same colorectal sensitivities and functional and neuroimmune abnormalities observed in human cases. These include increased growth factor and cytokine expression, such as NGF, IL-6, IL-1β, IL-2, IL-4, IL-10, and interferon (IFN)-γ, as well as infiltration of mast cells, in the distal colon, all of which can sensitize peripheral nociceptors and enhance visceral perception (Barreau et al., 2004a,b; Daniels et al., 2009; van den Wijngaard et al., 2009, 2012; O’Malley et al., 2011a,b; Lennon et al., 2013). While these studies have all been performed in rat models, studies from our lab using mice have revealed little to no effect of NMS on colorectal sensitivity, cytokine expression, or mast cell infiltration, with the exception of increasing susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis in male mice (Fuentes et al., 2016; Pierce et al., 2016). One other study on NMS in mice reported an increase in colonic hypersensitivity; however, this model also incorporated unpredictable maternal stress with unpredictable NMS, which likely altered the outcomes of this study, as it relates to our findings (Moloney et al., 2012). Other recent studies have highlighted the influence that the gut microbiota has on stress-related gastrointestinal disorders (Moloney et al., 2016), which can be impacted by age, sex, diet, genotype, and environment (Laukens et al., 2016), making it difficult to compare the outcomes of similar studies even in the same strain of mice. It is likely that contributing variables outside of species, sex, strain, and stressor-type will emerge as this field continues to move forward.

The chief complaints of IC/PBS patients include idiopathic pelviperineal pain and increased urinary urgency and frequency. Diagnosis of IC/PBS is largely symptom-based, particularly irritative voiding and referred lower urinary tract pain, after excluding other pathologies that mimic symptoms of IC/PBS (e.g., urinary tract infection; Hanno et al., 2011). As with other functional pain disorders, IC/PBS patients are more likely to have a history of early life stress or adversity. In a study of 87 female patients with IC/PBS, just over half reported a history of abuse, the majority of which occurred during childhood or adolescence (Peters et al., 2008). In another study of 207 female IC/PBS patients, 24% reported sexual abuse prior to the age of 17, compared to 15% in the control group. Those IC/PBS patients with a history of abuse had greater comorbid depression, anxiety, and mental functioning, as well as greater pain, but not functional symptoms, than those who did not report abuse (Nickel et al., 2011). Patients with IC/PBS who reported childhood trauma perpetuated by someone with whom they had a close relationship had a greater degree of comorbid anxiety, despite similar urogenital symptom severity, compared to IC/PBS patients without a history of abuse (Chiu et al., 2017). Multiple studies have reported that patients with IC/PBS have a higher incidence of childhood bladder problems, including recurrent urinary tract infections (Jones and Nyberg, 1997; Peters et al., 2008).

Similar to the aforementioned fMRI study illustrating increased functional connectivity in the emotional-arousal circuit of IBS patients, multiple studies have investigated changes in brain connectivity in patients with IC/PBS. Patients with more widespread pain, affecting multiple and disparate parts of the body outside of the pelvis, had greater increases in gray matter volume and functional connectivity of sensorimotor and insular cortices (Kutch et al., 2017). These changes also correlated with decreased physical and mental function. A separate study also correlated widespread pain with increased comorbid anxiety and depression and a lesser quality of life (Lai et al., 2017). While these studies do not directly address the role of the HPA axis or early life stress, the evidence linking these occurrences with comorbidity of mood disorder suggest that these patients may have a higher likelihood of early adverse events and/or increased activation of the HPA axis. In support of the latter, molecular and histological evidence of increased CRF signaling is present in tissue samples, serum, and/or urine from IC/PBS patients. Tissue biopsies from IC/PBS patients have revealed increased mast cell infiltration (Kastrup et al., 1983; Christmas and Rode, 1991; Spanos et al., 1997; Peeker et al., 2000; Tomaszewski et al., 2001; Larsen et al., 2008) and close proximity to densely-populated substance P (SP)-immunopositive nerve fibers (Pang et al., 1995). Mast cell tryptase was elevated in IC/PBS urine (Boucher et al., 1995; Okragly et al., 1999) and elevated NGF levels in seminal plasma have been demonstrated to be directly correlated with pain severity (Miller et al., 2002; Watanabe et al., 2011). Elevated concentrations of NGF, histamine, and pro-inflammatory cytokines have also been observed in IC/PBS patients’ serum (Jiang et al., 2013) and urine (Yun et al., 1992; Lotz et al., 1994; Jacobs et al., 2010; Corcoran et al., 2013).

CRF is not only involved in inflammation and pain signaling in the context of IC/PBS, BN, located in the dorsolateral pontine tegmentum, is central to the micturition pathway and uses CRF as a neurotransmitter within this relay (Vincent and Satoh, 1984; Sakanaka et al., 1987; Valentino et al., 1995). Neurons from the BN project to the lumbosacral parasympathetic nucleus, where preganglionic neurons innervate the pelvic viscera, and send collateral branches to the locus coeruleus (Sasaki, 2005; Valentino et al., 2011). Information relayed by bladder afferents from both the spinal cord, as well as the periaqueductal gray region (Blok et al., 1995; Ding et al., 1997; Rouzade-Dominguez et al., 2003b), stimulates BN neurons to induce increases in bladder pressure, cause bladder contraction, inhibit the external urethral sphincter, and relax the urethra (Sasaki, 2005). Activation of the locus coeruleus increases arousal and shifts the mode of attention to modify behavior to best coordinate visceral functions, such as voiding, through dense projections throughout the cortex (Berridge and Waterhouse, 2003; Aston-Jones and Cohen, 2005). Neurons in the BN have been shown to be sympathetically linked to and able to influence the distal colon, genitals, and bladder, allowing for co-regulation of multiple organ systems under certain conditions, such as stress (Marson, 1995; Marson and McKenna, 1996; Rouzade-Dominguez et al., 2003a). This organization may contribute towards the comorbidity of multiple pelvic visceral symptoms as CRF may play a role in regulating bladder or colonic motility as a component of the stress response (Valentino et al., 1999). Repeated social defeat stress in adult rats has been shown to increase CRF expression within BN (Kiddoo et al., 2006; Wood et al., 2009) and promote urine retention (Wood et al., 2009). Excitatory effects of CRF on colonic motoneurons may contribute to stress-related increases in colonic motility and symptoms of IBS (Pavcovich et al., 1998; Valentino et al., 1999); however, in vivo cystometry studies have suggested both excitatory and inhibitory effects of CRF on micturition by evaluating the effects of CRF and CRF antagonists administered systemically or intrathecally (Klausner and Steers, 2004; Klausner et al., 2005; Kiddoo et al., 2006). Treatment with CRF₁ antagonist reduced both bladder filling and micturition volumes that were initially increased due to intrathecal administration of CRF or Ucn2 (Kiddoo et al., 2006). Klausner et al. (2005), however, observed the opposite effect. CRF administration decreased micturition volume in normal Wistar rats, and intrathecal administration of astressin, a non-selective CRF₁/CRF₂ antagonist, increased void volumes of high-anxiety Wistar-Kyoto rats (Klausner et al., 2005). The exact role of CRF expression in BN in humans, particularly as it relates to IC/PBS, has yet to be elucidated, however these studies and others suggest it may play a pivotal role in stress-related symptomology.

Preclinical models incorporating early life stress and bladder inflammation have been used to investigate possible mechanisms underlying IC/PBS. Rats treated with intravesicular zymosan, an irritant component of the yeast cell wall, on postnatal days 14 and 16 displayed increased micturition frequency and heightened VMR and arterial blood pressure during urinary bladder distension (UBD) following reinflammation with zymosan as adults (Randich et al., 2006). Later investigations into this model revealed disruption of descending inhibitory pathways (DeBerry et al., 2007) and increased plasma extravasation and neuropeptide release after intravesicular mustard oil application (DeBerry et al., 2010). Studies from our laboratory showed that NMS in female mice increases the VMR during UBD both at baseline and following an acute exposure to WAS (Pierce et al., 2016). Bladder mast cell degranulation and pro-inflammatory gene expression profiles were significantly increased in female NMS mice, along with molecular evidence of altered hippocampal input onto the HPA axis. Stress-induced bladder hypersensitivity, vascular permeability, and upregulated peripheral expression of TNF-α and IL-10 in adult rat models have been described as being driven by a CRF₂ rather than a CRF₁-mediated mechanism (Robbins and Ness, 2008; Huang et al., 2009; Boucher et al., 2010; Novembri et al., 2011). Intrathecal administration of a CRF₂ antagonist prior to UBD attenuated unpredictable footshock-induced urinary bladder hypersensitivity as measured by VMR (Robbins and Ness, 2008).

CP/CPPS is characterized by chronic, idiopathic pain in the lower abdomen, rectum, perineum, prostate, penis, and/or testicles, with or without urinary symptoms (Duloy et al., 2007; Murphy et al., 2009), and is diagnosed symptomatically due to the lack of associated pathology (Pontari and Ruggieri, 2004). CP/CPPS has detrimental effects on quality of life, comparable to myocardial infarction, angina, Crohn’s disease, and diabetes (Murphy et al., 2009; Strauss and Dimitrakov, 2010). Little is known regarding the influence of early life stress or adversity on the later development of CP/CPPS; however, the significant overlap with IC/PBS and susceptibility to stress suggests a potential early life component to the disorder. Additionally, because male patients have been reported to experience significant psychological disturbances (McNaughton Collins et al., 2001; Tripp et al., 2006; Anderson et al., 2008, 2009; Nickel et al., 2008; Shoskes et al., 2009; Ahn et al., 2012; Riegel et al., 2014) similar to female patients that have experienced early life stress (Heim et al., 1998, 2002; Mayson and Teichman, 2009; Nickel et al., 2010; Warren et al., 2011a, b), it has been hypothesized that men with CP/CPPS may have similar histories. Findings from the Multi-Disciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network reported that both male and female patients suffering from urologic chronic pelvic pain syndromes (UCPPS; specifically, CP/CPPS in males and IC/PBS in females) exhibit greater psychological distress, poorer coping, higher levels of current and lifetime stress, and more widespread pain symptoms that contribute to poorer self-reported quality of life than sex- and education-matched healthy controls. The study goes on to report that individuals living with UCPPS experience greater incidences of early life and adult trauma compared to healthy controls (though women more significantly than men; Naliboff et al., 2015). To our knowledge, only one study has looked explicitly at the prevalence of early childhood trauma and developing CP/CPPS in adulthood: the Boston Area Community Health (BACH) survey examined the relationship between sexual, physical, or emotional abuse and symptoms suggestive of CP/CPPS. Hu et al. (2007) concluded that among the 2301 men recruited, reporting abuse increased the odds of also presenting symptoms suggestive of CP/CPPS, though greater frequency of both childhood and adult abuse were associated with increased prevalence of CP/CPPS symptomology. Furthermore, if a subject reported more than one type of abuse, he was at increased odds of reporting both increased pain and urinary scores of the NIH chronic prostatitis symptom index (CPSI), suggesting a cumulative effect (Hu et al., 2007).

As with the other chronic pelvic pain syndromes, the etiology underlying CP/CPPS is largely unknown, although stress has been shown to worsen or bring on symptoms. Evidence of altered HPA axis functioning has been demonstrated primarily by increased mast cell activation in the affected tissue. Though studies have reported varied degrees of mast cell degranulation and activation, CP/CPPS biopsies were observed having altered granular structure (Theoharides et al., 1990) and decreased numbers of intact mast cells (Amir et al., 1998), suggesting that mast cell activation without complete degranulation and increased rate of complete degranulation could occur in CP/CPPS. Concentrations of tryptase and carboxypeptidase A (CPA3), a marker of mast cell activation, were increased in urine samples from CP/CPPS patients (Roman et al., 2014). Mast cell tryptase and NGF levels were also increased in expressed prostatic secretions from patients (Done et al., 2012). Furthermore, Anderson et al. (2008, 2009) have reported that men with CP/CPPS, compared to healthy controls, have a greater slope of waking cortisol response (Anderson et al., 2008) and delayed ACTH release correlating with significant psychological disturbances (phobic anxiety, perceived stress, depression, etc.) in response to an acute stress (Anderson et al., 2009), suggesting altered HPA axis function.

The majority of published rodent models of CP/CPPS are centered around experimental infection; injection of exogenous antigens, androgens, or irritants (Pierce and Christianson, 2015); or invasive surgery (Vykhovanets et al., 2007) and, as such, are largely undefined in their mechanism of CP/CPPS development. We have recently begun investigating the use of NMS in mice as a model of CP/CPPS. Adult male NMS mice display significant perigenital mechanical hypersensitivity, as well as significantly increased mast degranulation in the prostate and bladder (Fuentes et al., 2015; current issue). This model also displays increased micturition frequency and output and molecular evidence of altered HPA functioning (current issue). Further investigation of NMS in mice will hopefully provide a more clinically relevant rodent model of CP/CPPS for investigation of potential therapies and interventions.

Vulvodynia presents clinically as vulvar discomfort, most often as a burning pain, with no identifiable pathological or neurological evidence of disease (Moyal-Barracco and Lynch, 2004). Although there is variability in clinical presentation, the hallmark symptom is allodynia and/or burning, stinging, or itching of the vulva, vestibule, or vaginal canal (McKay, 1988; Edwards, 2004). Early life adverse events are strongly linked with an increased likelihood of vulvodynia in adulthood and are attributed to dysfunctional regulation of the HPA axis. Vulvodynia was strongly associated with a sense of danger or abuse, particularly by a primary family member, during childhood (Harlow and Stewart, 2005). A separate study did not find an increase in childhood abuse; however, parental divorce was more common among women with vulvodynia when compared to controls (Plante and Kamm, 2008). In a survey of women diagnosed with IC/PBS, 63% reported vulvar pain and 29% reported a history of abuse (Carrico et al., 2009). Women with vulvodynia have blunted serum cortisol cycles (Ehrström et al., 2009) and, like with other chronic pelvic pain syndromes, symptom severity is increased following acute stress exposure (Gordon et al., 2003). Defective regulation of the downstream inflammatory response is also observed as increased mast cell degranulation and infiltration within vestibular biopsies when compared to controls (Bornstein et al., 2008). Mast cell-derived heparanase is increased in the vestibule of vulvodynia patients (Bornstein et al., 2008), where it serves to degrade the heparin sulfate component of basement membranes and the extracellular matrix as needed for leukocyte infiltration (Goldberg et al., 2013). Age-related changes have been observed, as mast cell activation increases in post- compared to pre-menopausal vulvodynia patients, despite similar expression levels of estrogen receptor α and evidence of neural hyperplasia (Leclair et al., 2013). Increases in proinflammatory cytokines IL-1 and TNF-α have also been reported (Foster and Hasday, 1997; Jeremias et al., 2000), both of which have been demonstrated to be produced by activated mast cells (Galli et al., 2005). Moreover, decreased IL-1 receptor antagonist (IL-1RA) activity has been observed in vulvodynia patients, and has been associated with increased IL-1 beta activity, which has been observed in tissues sampled from patients (Foster et al., 2007). Inflammatory challenge in patients resulted in blunted IL-1RA response (Gerber et al., 2002). The prevention of stress-induced elevations in IL-1β and associated increase of HPA axis activity by pretreatment with IL-1RA (Gądek-Michalska et al., 2011), suggests that peripheral cytokines can influence central perceptions of pain through limbic control.

Despite the clinical prevalence of vulvodynia, few animal models have been published investigating preclinical mechanisms possibly underlying this disorder. Animal models have exploited both the hormonal and allodynic characteristics of vulvodynia by observing peripheral neuron sprouting under low estrogenic conditions (Bhattacherjee et al., 2013), vulvar allodynia following repeated vulvovaginal fungal infection (Farmer et al., 2011), and oxazolone-induced delayed-type contact hypersensitivity of the vulva (Martinov et al., 2013). We have developed two separate preclinical models of vulvodynia using NMS (Pierce et al., 2014) and NVI with zymosan (Pierce et al., 2015). Both models develop significant vaginal hypersensitivity in adulthood with associated increases in HPA axis gene expression levels and/or output. As mentioned above, the vaginal hypersensitivity in the NVI model was prevented by pretreating with CRF₁ antagonist prior to zymosan treatment, verifying the involvement of the HPA axis in the development of vaginal hypersensitivity (Pierce et al., 2015).